Literature DB >> 20609572

Dietary phosphate restriction in dialysis patients: a new approach for the treatment of hyperphosphataemia.

B Guida1, A Piccoli, R Trio, R Laccetti, A Nastasi, A Paglione, A Memoli, B Memoli.   

Abstract

BACKGROUND AND AIM: Elevated serum phosphate and calcium-phosphate levels play an important role in the pathogenesis of vascular calcifications in uraemic patients and appear to be associated with increased cardiovascular mortality. We aimed to evaluate the effects of a partial replacement of food protein with a low-phosphorus and low-potassium whey protein concentrate on phosphate levels of dialysis patients with hyperphosphataemia. METHODS AND
RESULTS: Twenty-seven patients undergoing chronic haemodialysis were studied for a 3-month period. In the intervention group (n = 15), food protein were replaced by 30 or 40 g of low-phosphorus and low-potassium protein concentrate aimed at limiting the phosphate intake. In the control group (n = 12) no changes were made to their usual diet. Anthropometric measurements, biochemical markers and dietary interviews were registered at baseline and during the follow-up period. From baseline to the end of the study, in the intervention group, serum phosphate and circulating intact parathyroid hormone levels lessened significantly (8.3 ± 1.2 mg/dL vs 5.7 ± 1.4 mg/dL and 488 ± 205 pg/ml vs 177 ± 100 pg/ml respectively; p < 0.05) with decreasing of phosphate and potassium intake. No significant differences were found in the control group. No significant changes were observed in serum albumin, calcium, potassium, Kt/V, body weight and body composition in both the intervention and control groups.
CONCLUSION: Dietary intake of phosphate mainly comes from protein sources, so dietary phosphorus restriction may lead to a protein/energy malnutrition in a dialysis patient. A phosphorus-controlled diet plan including a nutritional substitute resulted in serum phosphate and intact parathyroid hormone decrease without nutritional status modifications in dialysis patients.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609572     DOI: 10.1016/j.numecd.2010.02.021

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  7 in total

Review 1.  Contemporary management of phosphorus retention in chronic kidney disease: a review.

Authors:  Fateme Shamekhi Amiri
Journal:  Clin Exp Nephrol       Date:  2015-06-02       Impact factor: 2.801

2.  Short-Term Changes in Body Composition and Response to Micronutrient Supplementation After Laparoscopic Sleeve Gastrectomy.

Authors:  A Belfiore; M Cataldi; L Minichini; M L Aiello; R Trio; G Rossetti; B Guida
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

Review 3.  Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?

Authors:  Matthew Snelson; Rachel E Clarke; Melinda T Coughlan
Journal:  Nutrients       Date:  2017-03-11       Impact factor: 5.717

Review 4.  The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.

Authors:  Jiameng Li; Liya Wang; Mei Han; Yuqin Xiong; Ruoxi Liao; Yupei Li; Si Sun; Anil Maharjan; Baihai Su
Journal:  Nutr Diabetes       Date:  2019-04-03       Impact factor: 5.097

5.  Education and Protein Supplementation Improve Nutritional Biomarkers among Hypoalbuminemic Peritoneal Dialysis Patients: A Quasi-Experimental Design.

Authors:  Tuyen Van Duong; Chang-An Tsao; Evelyn Yang; Ching-Hsiu Peng; Yi-Cheng Hou; Yan-Chen Su; Jui-Ting Chang; Shwu-Huey Yang
Journal:  Healthcare (Basel)       Date:  2019-11-05

6.  Patient education for phosphorus management in chronic kidney disease.

Authors:  Kamyar Kalantar-Zadeh
Journal:  Patient Prefer Adherence       Date:  2013-05-03       Impact factor: 2.711

7.  Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study.

Authors:  Andrew Peter McGovern; Simon de Lusignan; Jeremy van Vlymen; Harshana Liyanage; Charles Richard Tomson; Hugh Gallagher; Meena Rafiq; Simon Jones
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.